If you have been reading about actin-binding motif and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
== Medical contributions == Eastlack's home, Philadelphia, has become a center for FOP research with much of it concentrated at the University of Pennsylvania. With his skeleton on display, doctors and professors alike lead students to the Mütter Museum to observe the result of the rare disorder in person. Since surgeries and examinations of FOP patients exacerbate the condition, the ability to study Eastlack's skeleton has been significant for research. For example, in 2006, University of Pennsylvania's team of researchers and scientists led by Frederick Kaplan was able to distinguish the particular gene responsible for the disease, the ACVR1 gene. It is said that Eastlack's skeleton was a useful reference for this medical discovery. The International FOP Association is also granted Eastlack's skeleton for displaying and informational purposes in medical meetings and international FOP symposia, which physicians, researchers, and patients attend. For example, over 43 families were recorded to have attended a two-day symposium hosted in Philadelphia in October 1995 to listen to orthopedic surgeons and physicians discuss the details of FOP. During this symposium, Eastlack's skeleton was used as a reference. After seeing his skeleton at this event, fellow FOP patient Carol Orzel decided to also donate her body to the museum. She died in February 2018, and in February 2019, her skeleton was put on display next to his.
=== Serotonin norepinephrine reuptake inhibitor === Venlafaxine (Effexor) from the SNRI class may be moderately more effective than SSRIs; however, it is not recommended as a first-line treatment because of the higher rate of side effects, and its use is specifically discouraged in children and adolescents.
This allowed for two Soviet Republics, Ukraine and Byelorussia, (as well as the USSR as a whole) to join the United Nations General Assembly as founding members in 1945. The Soviet currency Soviet ruble banknotes all included writings in national languages of all the 15 union republics. All of the former Republics of the Union are now independent countries, with ten of them (all except the Baltic states, Georgia and Ukraine) being very loosely organized under the heading of the Commonwealth of Independent States. The Baltic states assert that their incorporation into the Soviet Union in 1940 (as the Lithuanian, Latvian, and Estonian SSRs) under the provisions of the 1939 Molotov–Ribbentrop Pact was illegal, and that they therefore remained independent countries under Soviet occupation. Their position is supported by the European Union, the European Court of Human Rights, the United Nations Human Rights Council and the United States. In contrast, the Russian government and state officials maintain that the Soviet annexation of the Baltic states was legitimate.
Sources: en.wikipedia.org
Two main trends impinge on the industry. On the supply side, biotechnology is rapidly gaining importance. In the synthesis of small molecule fine chemicals, the use of biocatalysts and microbial fermentation enable both a more sustainable and economic production than conventional organic chemistry. In the synthesis of big molecules, such as biopharmaceuticals, it is the method of choice. Biopharmaceuticals are expected to grow 15% per year, three times as fast as small molecule drugs. Five of the top ten drugs were biopharmaceuticals in 2010 (see table 6), and this is expected to grow to eight by 2016 (see table 2). On the demand side, the main customer base for fine chemicals, the pharmaceutical industry, is faced with slower growth of demand, patent expirations of many lucrative blockbuster drugs and stalling new product launches. In order to restrain these challenges, the leading companies are implementing restructuring programs, including a reduction of in-house chemical manufacturing and plant eliminations. Outsourcing is moving from a purely opportunistic to a strategic approach. It is difficult to judge whether the positive or negative effects of these initiatives will prevail. In a worst-case scenario, a condition could develop whereby even top-tier mid-sized, family-owned fine-chemical companies with state-of-the-art plants and processes could be relegated to producing small quantities of fine chemicals for new life-science products in late stage of development. In agro fine chemicals, the active ingredients are become more sophisticated and better performing.
There have been calls for tapentadol to be only marketed in countries where appropriate controls exist, but after performing a critical review, the United Nations Expert Committee on Drug Dependence in 2014 advised that tapentadol not be placed under international control but remain under surveillance. As mentioned, the enhanced potency of tapentadol makes it considerably more susceptible to abuse compared to other opioids. This increased potency is one of the key factors that contribute to its higher potential for misuse. Furthermore, tapentadol is water soluble, which allows for a variety of methods to ingest or administer the drug. It can be snorted, inhaled, or even delivered rectally, all of which significantly increase the risk of abuse and the potential for dangerous consequences. These factors combined make tapentadol a particularly risky substance when it comes to misuse, posing serious concerns for both individuals and public health. The FDA's Controlled Substance Staff (CSS) recognizes that tapentadol is available as an immediate-release formula, and that in the past there was no requirement of a medication guide for immediate-release opioids. However, tapentadol exhibits several distinctive properties that makes it highly abusable. According to them:
== History == The first mention of armed groups of Chechen militants in Syria appeared in a number of media outlets at the end of 2011. In October 2012, some publications wrote that Chechens as part of the Syrian opposition forces of the FSA and Jabhat al-Nusra took part in an attack on the military base of the Syrian army air defense brigade near Aleppo. Chechen jihadists began arriving in Syria en masse mainly in 2011-2015 from Chechnya, as well as from Europe, where they left during the second Chechen War, fleeing from the war, as well as from the Pankisi Gorge of Georgia, where ethnic Chechens-Kistins, who emigrated there during the Caucasian War. Chechens occupied the second largest number among the foreign contingent of jihadists in Syria, estimates of their number range from 1,700 to 3,000 people, they played a significant role in the civil war in Syria, and several dozen well-known commanders of Syrian rebels and jihadists were Chechens by origin. Some of them were veterans of the first and second Chechen wars and used their combat experience to train the Syrian opposition and militants. They formed their own armed detachments and jamaats, which were also joined by other militants from the North Caucasus, as well as Syrians and jihadists from all over the Middle East. According to representatives of the Chechen diaspora in Europe, hundreds of Chechens from Europe went to Syria to fight in the ranks of the Syrian opposition against the government army of Bashar al-Assad.
People with MASLD often have no noticeable symptoms, and it is often only detected during routine blood tests or unrelated abdominal imaging or liver biopsy. In some cases, it can cause symptoms related to liver dysfunction such as fatigue, malaise, and dull right-upper-quadrant abdominal discomfort. Mild yellow discoloration of the skin may occur, although this is rare. MASH can severely impair liver function, leading to cirrhosis, liver failure, and liver cancer.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.